Filing Flows › Comparisons › KURA vs LAB
Kura Oncology vs Standard Biotools: KURA and LAB compared
Kura Oncology is the larger company: $20.9M of revenue in its latest quarter (Q2 2026) against $19.4M for Standard Biotools (Q3 2026). Kura Oncology is growing faster (+36% against -0.9% a year earlier). Standard Biotools is more profitable, with an operating margin of -102.0% against -349.8%.
Where the money goes: KURA and LAB
Kura Oncology (KURA) · Q2 2026
Kura Oncology, Q2 2026: revenue $20.9M (+36% year over year), operating margin -349.8%, net loss $68.3M, operating cash flow −$62.5M. The chart follows the revenue to costs, profit and cash.
Standard Biotools (LAB) · Q3 2026
Standard Biotools, Q3 2026: revenue $19.4M (-0.9% year over year), operating margin -102.0%, net earnings $13.5M, operating cash flow −$6.2M. The chart follows the revenue to costs, profit and cash.
| Kura Oncology (KURA) | Standard Biotools (LAB) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $20.9M | $19.4M |
| Revenue growth, Y/Y | +36% | -0.9% |
| Operating margin | -349.8% | -102.0% |
| Net earnings | −$68.3M | $13.5M |
| Net margin | -327.3% | 69.6% |
| Operating cash flow | −$62.5M | −$6.2M |
Where the revenue comes from
Kura Oncology
- License and Collaboration Revenue: $11.8M (56%)
- Product: $9.1M (44%)
Standard Biotools
- Product: $14.3M (74%)
- Services and Other Revenue: $5.1M (26%)
Questions
Which is bigger, Kura Oncology or Standard Biotools?
Kura Oncology is the larger company: $20.9M of revenue in its latest quarter (Q2 2026) against $19.4M for Standard Biotools (Q3 2026).
Is Kura Oncology or Standard Biotools growing faster?
Kura Oncology is growing faster (+36% against -0.9% a year earlier).
Which is more profitable, Kura Oncology or Standard Biotools?
Standard Biotools is more profitable, with an operating margin of -102.0% against -349.8%.
More: Kura Oncology earnings · how Kura Oncology makes money · Standard Biotools earnings · how Standard Biotools makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.